Headquartered in New Haven, CT, Achillion is a leading-edge pharmaceutical company advancing multiple candidates with proven mechanisms for the treatment of HCV. Click here for more information about Achillion's ongoing clinical trials.
Hepatitis C is a worldwide epidemic affecting more than 170 million individuals. Click to learn more about this disease.
No upcoming events at this time.
Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes
Achillion to Present at Two Upcoming Investor Conferences